PATENT CLAIM ANALYSIS

Application Number: 16188784
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-04
Patent Classification: ["549", "448000"]

Abstract:
The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

Claim (Index 18):
A pharmaceutical composition comprising an acid labile lipophilic molecular conjugate (ALLMC) of the formula  1 : wherein:\n R is a 2\u2032 hydroxyl residue of a paclitaxel, a docetaxel or an abeo-taxane compound; \n R 1  is hydrogen; \n R 2  is a C 5 -C 22  alkyl; \n Y is selected from O, NR\u2032 or S wherein R\u2032 is hydrogen or C 1 -C 6  alkyl; \n Z is O or S; \n Q is O; and T is O; \n or an enantiomer, diastereoisomer or mixtures thereof; and a pharmaceutically acceptable salt thereof; wherein the acid labile lipophilic molecular conjugate (ALLMC) is dissolved in the lipid core of a pseudo-LDL particle; and the pharmaceutical composition is formulated as a liquid formulation or solution for parenteral administration.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 549.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15675399', '13856216', '13489247', '14217074', '15131318']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8254122679669267
- 35 USC 102 Novelty (BERT): 0.6472327799663808
- Combined Prediction Score: 0.8075943191668722
- Mean Citation Score: 569.79196
- Max Citation Score: 612.5234
- Similarity Product: 607.6338635674714

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test